


Singapore maps future of biomanufacturing industry & catalyses recovery

04 April 2022 | News

With two years of severe supply chain disruption and uncertainty at its back, the biopharma logistics profession has come forward with ingenuity to deliver life-critical vaccines, therapies and other products across complicated geographies.



The *9th Annual Biologics Manufacturing Asia 2022* & the *6th Annual BioLogistics World Asia 2022* conferences concluded with industry views on post pandemic biomanufacturing and a focus on the future of Asia's Bioprocessing sector.

The annual event gathered biologics and vaccine experts from all over the world at Suntec Convention Center from 29th to 31st March 2022. Over 1,000+ participants and 400+ companies attended from 50 countries, representing more than 50% of the world's top manufacturers of biologics.

The conference presents thought leaders the opportunity to exchange views on the optimism in Asia Pacific's biologics & vaccine manufacturing and biologistics projected growth and how industry players can link arms to build a better future as well as scaling up the next wave of innovation.

The Biomedical Manufacturing industry in Singapore constituted 4% of Singapore's GDP with a potential for growth as we prepare for future pandemics. By bringing key stakeholders together in Singapore, a knowledge exchange such as this can spur investment and job growth in the BioPharma space, said Sumukhi Sreevatsan, General Manager, IMAPAC Singapore.

Amid all the uncertainties, the biopharma industry has faced disruptions of its own.

With two years of severe supply chain disruption and uncertainty at its back, the biopharma logistics profession has come forward with ingenuity to deliver life-critical vaccines, therapies and other products across complicated geographies. In recognition of this, the BioLogistics World Asia conference forefronted several case studies by companies on the front line as well as keynotes from NGOs like UNICEF and GAVI covering the vaccine rollout efforts and analysis.

Several companies came together to present the latest ideas and technologies, including *Pfizer, Gilead Sciences, Samsung Biologics, Regeneron, Serum Institute of India, Novartis, Chugai Pharma, Amgen, Astra-Zeneca, GenScript, Merck, Cerecin, and Hetero Labs*, that will catalyse this transformation.